Turshudzhyan A, Samuel S, Tawfik A, Tadros M. Rebuilding trust in proton pump inhibitor therapy. World J Gastroenterol 2022; 28(24): 2667-2679 [PMID: 35979162 DOI: 10.3748/wjg.v28.i24.2667]
Corresponding Author of This Article
Micheal Tadros, FACG, MD, Associate Professor, Department of Gastroenterology and Hepatology, Albany Medical College, 49 New Scotland Ave, Albany, NY 12208, United States. tadrosm1@amc.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jun 28, 2022; 28(24): 2667-2679 Published online Jun 28, 2022. doi: 10.3748/wjg.v28.i24.2667
Rebuilding trust in proton pump inhibitor therapy
Alla Turshudzhyan, Sonia Samuel, Angela Tawfik, Micheal Tadros
Alla Turshudzhyan, Department of Medicine, University of Connecticut, Farmington, CT 06030, United States
Sonia Samuel, Department of Medicine, Albany Medical College, Albany, NY 12208, United States
Angela Tawfik, Guilderland High School, Guilderland Center, Albany, NY 12085, United States
Micheal Tadros, Department of Gastroenterology and Hepatology, Albany Medical College, Albany, NY 12208, United States
Author contributions: Turshudzhyan A, Samuel S, and Tawfik A wrote the manuscript; Tadros M revised the manuscript.
Conflict-of-interest statement: There are no conflicts of interest to report.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Micheal Tadros, FACG, MD, Associate Professor, Department of Gastroenterology and Hepatology, Albany Medical College, 49 New Scotland Ave, Albany, NY 12208, United States. tadrosm1@amc.edu
Received: January 10, 2022 Peer-review started: January 10, 2022 First decision: March 8, 2022 Revised: March 15, 2022 Accepted: May 8, 2022 Article in press: May 8, 2022 Published online: June 28, 2022
Core Tip
Core Tip: Proton pump inhibitor (PPI) therapy is a cornerstone therapy for acid-related diseases. Its clinical success can be attributed to anti-secretory properties superior to any prior agents and seemingly low side-effects profile. As more patients were started and continued PPI therapy long-term, some studies began reporting side-effects associated with this therapy. Concerns over risks associated with PPI use grew over the last couple of years among both patients and providers. We hope to bring awareness to the current guidelines and the evidence behind the reported side-effects as better understanding of this evidence can improve medical practice. Both patients and providers should have all the evidence at hand when discussing initiation or continuation of PPI therapy.
